Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Northwest Biotherapeutics

Northwest Biotherapeutics
1996 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
NWBO STOCK SYMBOL
1 INVESTMENTS
$0.27 SHARE PRICE (As of Friday Closing)
Description

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Website
Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
PINX
Primary Office
  • 4800 Montgomery Lane
  • Suite 800
  • Bethesda, MD 20814
  • United States

+1 (240) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Northwest Biotherapeutics’s full profile, request a free trial.

Northwest Biotherapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.17 - $0.35 $156M $0.28 -$0.02 1.49M 579M

Northwest Biotherapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 148,340 157,162 100,252 73,624
Revenue 1,373 412 336 623
EBITDA (7,949) (24,632) (67,159) (76,207)
Net Income (13,799) (35,794) (73,143) (80,214)
Total Assets 14,704 24,667 48,907 52,906
Total Debt 21,126 16,797 31,429 31,711
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Northwest Biotherapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Northwest Biotherapeutics‘s full profile, request access.

Request full access to PitchBook

Northwest Biotherapeutics Competitors (41)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Advanced Proteome Therapeutics Corporate Backed or Acquired Boston, MA 0 00.000 000000000 00.000
0000000 Formerly PE-Backed Beijing, China 0000 00.000 00000000 00.000
00000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
000 000000000000 Venture Capital-Backed Epalinges, Switzerland 000 00000 00000000 00000
000000 00000000000 Venture Capital-Backed Weston, FL 000.00 000000 - 000 000.00
To view this company’s complete list of competitors, request access »

Northwest Biotherapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 01-Jan-2008 000000000000000000 Biotechnology
To view this company’s complete investment and acquisition history, request access »

Northwest Biotherapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Northwest Biotherapeutics‘s full profile, request access.

Request full access to PitchBook

Northwest Biotherapeutics Executive Team (7)

Name Title Board
Seat
Contact
Info
Marnix Bosch Ph.D Chief Technology Officer
Alton Boynton Ph.D Chief Scientific Officer & Founder
Linda Powers JD Chief Executive Officer & Chief Financial Officer

4 Former Executives

You’re viewing 3 of 7 executives. Get the full list »

Northwest Biotherapeutics Board Members (5)

Name Representing Role Since Contact
Info
00000 0000000000 Northwest Biotherapeutics Board Member 000 0000
0000000 000000000 Self Director 000 0000

3 Former Board Members

You’re viewing 2 of 5 board members. Get the full list »